rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Enovis Corporation

ENOV · NYSE

Health CareMedical DevicesNot moving yet

ENOV stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 7 weeks. It is 14.2% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 7
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$1.5M
Insider sales, 12 months
$45K
Officials’ trades on record
5
Institutions holding
232 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$865KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

5 disclosed lines: House 0, Senate 0, executive 5; 1 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k26 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k26 Jan 2026filed 14 May 2026

Insiders

Buy orders, 12 months16
Sale orders, 12 months1
Buyers · sellers3 · 1
WhoDidSharesTraded
Damien McDonaldChief Executive Officerbought13,035at $19.154 Sep 2026filed 4 Sep 2026
Oliver EngertChief Administrative Officerbought2,660at $18.804 Sep 2026filed 8 Sep 2026
Oliver EngertChief Administrative Officerbought5,140at $19.463 Sep 2026filed 4 Sep 2026
Oliver EngertChief Administrative Officerbought2,458at $20.322 Sep 2026filed 4 Sep 2026
Oliver EngertChief Administrative Officerbought1,000at $20.9215 Jun 2026filed 16 Jun 2026
Oliver EngertChief Administrative Officerbought200at $20.9911 Jun 2026filed 15 Jun 2026
Oliver EngertChief Administrative Officerbought1,000at $21.7511 Jun 2026filed 15 Jun 2026
Oliver EngertChief Administrative Officerbought1,000at $23.0010 Jun 2026filed 11 Jun 2026
Oliver EngertChief Administrative Officerbought1,000at $22.221 Jun 2026filed 3 Jun 2026
Oliver EngertChief Administrative Officerbought1,000at $23.7413 Mar 2026filed 16 Mar 2026
Oliver EngertChief Administrative Officerbought1,000at $23.9310 Mar 2026filed 12 Mar 2026
Oliver EngertChief Administrative Officerbought1,000at $23.399 Mar 2026filed 10 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders232-2 on the quarter
New · exited42 · 44
Reported value$1.5B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202610,295,666$213.1M+359,197+3.6%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20266,106,561$126.4M+1,337,640+28.0%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20263,926,268$81.3M+117,639+3.1%
Rubric Capital Management LPadded · filed 14 Aug 20263,900,000$80.7M+1,446,735+59.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20262,484,318$51.4M-68,033−2.7%
STATE STREET CORPadded · filed 7 Aug 20262,462,788$51.0M+60,553+2.5%
DAVENPORT & Co LLCreduced · filed 13 Jul 20262,341,521$48.5M-96,720−4.0%
Hood River Capital Management LLCadded · filed 14 Aug 20262,299,326$47.6M+542,657+30.9%
FMR LLCadded · filed 13 Aug 20262,208,811$45.7M+846,214+62.1%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20261,772,577$36.7M+204,429+13.0%
31 Mar 2023 – 30 Jun 2026
207233258Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christine Ortiz Company insiderDirector · last 30 Sep 20260 · 0
Damien McDonald Company insiderChief Executive Officer · last 4 Sep 20262 · 0
Oliver Engert Company insiderChief Administrative Officer · last 4 Sep 202614 · 0
Donald J. Trump Executive branchWhite House Office · last 4 Jun 20262 · 3
A. Clayton Perfall Company insiderDirector · last 19 May 20261 · 1
Angela S. Lalor Company insiderDirector · last 19 May 20260 · 0
Barbara W. Bodem Company insiderDirector · last 19 May 20260 · 0
Brady Shirley Company insiderDirector · last 19 May 20261 · 8
Liam Kelly Company insiderDirector · last 19 May 20261 · 0
Philip Okala Company insiderDirector · last 19 May 20260 · 0
Rajiv Vinnakota Company insiderDirector · last 19 May 20260 · 11
Sharon L. Wienbar Company insiderDirector · last 19 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202559.8%
Operating profit marginFY 2025 · to 31 Dec 2025-50.0%
Free cash flow marginFY 2025 · to 31 Dec 20250.9%
Return on capital employedFY 2025 · to 31 Dec 2025-34.7%
Debt to equityFY 2025 · to 31 Dec 20250.89×
Interest coverFY 2025 · to 31 Dec 2025-32.28×
Research spendFY 2025 · to 31 Dec 20255.4%
Share count trendFY 2025 · to 20 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$36.4M
Free cash flowFY 2025 · to 31 Dec 2025$19.9M

Analyst forecasts

No analyst forecasts yet.